• Cy5 Maleimide (Non-sulfonated): Precision Thiol Labeling for

  2026-05-19

  Cy5 maleimide (non-sulfonated) enables high-specificity thiol labeling, supporting robust fluorescence-based detection of proteins. Its strong extinction coefficient and site-selective reactivity make it a gold standard for protein labeling with maleimide dyes. This article details its mechanism, evidence base, and practical workflow integration.

• Angiotensin III (human, mouse): Reliable RAAS Peptide for As

  2026-05-18

  Inconsistent outcomes in cell viability and receptor signaling studies often stem from peptide variability and protocol uncertainty. This article provides scenario-driven, evidence-based guidance for leveraging Angiotensin III (human, mouse) (SKU A1043) as a robust, quality-controlled tool. Readers will find actionable Q&A, protocol parameters, and candid product selection insights for reproducible cardiovascular and neuroendocrine workflows.

• Cand2 Modulates Ubiquitination and Autophagy in Rice Blast F

  2026-05-18

  Zhang et al. uncover Cand2 as a critical inhibitor of CRL-mediated ubiquitination in Magnaporthe oryzae, thus suppressing autophagy and enhancing fungal pathogenicity. This mechanistic insight links protein homeostasis pathways to fungal virulence, offering new directions for plant-pathogen research.

• Cisplatin (A8321): Mechanistic Insights and Next-Gen Assays

  2026-05-17

  Explore the molecular action of Cisplatin in cancer research, with a unique focus on resistance mechanisms and advanced assay design. Unlock deeper understanding for apoptosis and tumor inhibition studies.

• Cisplatin (CDDP): Mechanism, Evidence, and Protocols in Canc

  2026-05-16

  Cisplatin (CDDP) is a benchmark chemotherapeutic agent that induces apoptosis in cancer cells via DNA crosslinking, making it indispensable for cancer research. Its efficacy, mechanisms of action, and experimental use are well-documented in peer-reviewed literature. This article details the biological rationale, verifiable mechanisms, and best-practice protocols for Cisplatin from APExBIO.

• Optimizing Cisplatin (CDDP) Workflows for Tumor Inhibition A

  2026-05-15

  Cisplatin (CDDP) remains indispensable for dissecting apoptosis and tumor growth inhibition in cancer research, especially in the face of chemotherapy resistance. This article delivers actionable protocol guidance, troubleshooting strategies, and translational insights—anchored by new findings in metabolic reprogramming—to drive more robust and reproducible outcomes in both in vitro and in vivo models.

• Protein A/G Magnetic Beads: Next-Gen Precision in Cancer Ste

  2026-05-15

  Explore how Protein A/G Magnetic Beads empower advanced immunoprecipitation and protein-protein interaction studies in cancer stem cell research. Discover distinct protocol insights, deeper mechanistic analysis, and practical guidance for translational oncology.

• GRP78 Stabilizes PD-L1 and Promotes Immune Evasion in TNBC

  2026-05-14

  This study uncovers the endoplasmic reticulum (ER) stress protein GRP78 as a novel stabilizer of PD-L1 in triple-negative breast cancer (TNBC), showing that GRP78 directly interacts with PD-L1 and regulates its stability under ER stress. The findings reveal a mechanistic basis for chemotherapy-induced immune evasion and suggest targeting GRP78 as a strategy to enhance immunotherapy efficacy.

• (S)-(+)-Ibuprofen: COX Inhibition Rethought for Translationa

  2026-05-14

  This thought-leadership article redefines (S)-(+)-Ibuprofen’s role in translational inflammation and pain mechanism research. By integrating mechanistic insights, contemporary synthesis perspectives, and strategic experimental guidance, we provide a roadmap for researchers aiming to unlock the full translational and clinical potential of this selective COX inhibitor. The discussion is anchored in recent peer-reviewed advances and addresses both experimental challenges and clinical realities, while positioning APExBIO’s (S)-(+)-Ibuprofen as a uniquely rigorous tool for next-generation studies.

• Protease and Phosphatase Inhibitor Cocktail: Mechanistic Sci

  2026-05-13

  Discover how the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O) preserves protein integrity and phosphorylation states in complex biological samples. This article offers a unique, mechanistic deep dive tied to the latest cell signaling research.

• Talabostat Mesylate: Bridging DPP4/FAP Inhibition to Tumor I

  2026-05-13

  This thought-leadership article explores Talabostat mesylate (PT-100) as a dual DPP4 and FAP inhibitor, situating its mechanistic action within the evolving landscape of tumor microenvironment modulation and immune activation. By integrating foundational insights, recent advances in inflammasome biology, and practical guidance for translational researchers, the discussion advances beyond conventional product overviews. Cited evidence, strategic outlook, and protocol parameters equip research teams for next-generation oncology and immunomodulation studies.

• CARD8 Inflammasome Triggers Pyroptosis in Human T Cells via

  2026-05-12

  Linder et al. reveal that inhibition of dipeptidyl peptidases by Val-boroPro (Talabostat mesylate) activates the CARD8 inflammasome, inducing pyroptotic cell death in human T cells. This finding extends inflammasome signaling relevance beyond myeloid cells, highlighting new immunological mechanisms and research opportunities.

• OMV-Based mRNA Antigen Display for Personalized Tumor Vaccin

  2026-05-12

  This article examines a novel strategy using bacteria-derived outer membrane vesicles (OMVs) engineered to rapidly display and deliver mRNA antigens for personalized tumor vaccination. The approach enables efficient mRNA uptake by dendritic cells, robust immune activation, and significant tumor regression, offering a promising alternative to lipid nanoparticle-based delivery systems.

• 3D Organoid-Fibroblast Co-Cultures Reveal Chemoresistance Dr

  2026-05-11

  Schuth et al. present a patient-specific 3D organoid-fibroblast co-culture system that models stroma-mediated chemoresistance in pancreatic ductal adenocarcinoma (PDAC). This approach uncovers key tumor-stroma interactions, including EMT induction and pro-inflammatory CAF phenotypes, with implications for personalized drug screening and translational research.

• Diclofenac (SKU B3505): Reliable COX Inhibition for Advanced

  2026-05-11

  This scenario-driven guide explores how Diclofenac (SKU B3505) addresses core challenges in cell-based inflammation, proliferation, and pharmacokinetic assays. By integrating high-purity, robustly validated Diclofenac from APExBIO into experimental workflows, researchers can maximize reproducibility and interpretability in cutting-edge organoid and cell viability studies.

16361 records 1/1091 page Next 12345 下5页 Last page